Evidence map›Paper›PMID 36538240›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2023

Establishment of experimental salivary gland cancer models using organoid culture and patient-derived xenografting.

Yoshihiro Aizawa, Kentaro Takada, Jun Aoyama, Daisuke Sano, Shoji Yamanaka, Masahide Seki, Yuta Kuze, Jordan A Ramilowski, Ryo Okuda, Yasuharu Ueno and 10 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 2 countries.

Yoshihiro AizawaDepartment of Otorhinolaryngology, Head and Neck Surgery, School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan.
Kentaro TakadaDepartment of Otorhinolaryngology, Head and Neck Surgery, School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan.
Jun AoyamaDepartment of Otorhinolaryngology, Head and Neck Surgery, School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan.
Daisuke SanoDepartment of Otorhinolaryngology, Head and Neck Surgery, School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan. dsano@yokohama-cu.ac.jp.ORCID http://orcid.org/0000-0002-7686-4724
Shoji YamanakaDepartment of Pathology, Yokohama City University Hospital, Yokohama, Kanagawa, Japan.
Masahide SekiDepartment of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Chiba, Japan.
Yuta KuzeDepartment of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Chiba, Japan.
Jordan A RamilowskiAdvanced Medical Research Center, Yokohama City University, Kanagawa, Japan.
Ryo OkudaRoche Innovation Center, Roche Institute for Translational Bioengineering, Roche Pharma Research and Early Development, Basel, Switzerland.
Yasuharu UenoDivision of Regenerative Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, the University of Tokyo, Tokyo, Japan.
Yusuke NojimaDepartment of Otorhinolaryngology, Head and Neck Surgery, School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan.
Yoshiaki InayamaDepartment of Pathology, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan.
Hiromitsu HatakeyamaDepartment of Otolaryngology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan.
Takashi HatanoDepartment of Otorhinolaryngology, Head and Neck Surgery, School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan.
Hideaki TakahashiDepartment of Otorhinolaryngology, Head and Neck Surgery, School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan.
Goshi NishimuraDepartment of Otorhinolaryngology, Head and Neck Surgery, School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan.
Satoshi FujiiDepartment of Molecular Pathology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan.
Yutaka SuzukiDepartment of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Chiba, Japan.
Hideki TaniguchiDivision of Regenerative Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, the University of Tokyo, Tokyo, Japan.
Nobuhiko OridateDepartment of Otorhinolaryngology, Head and Neck Surgery, School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan.
Yokohama City University · JPThe University of Tokyo · JPYokohama City University Medical Center · JPRoche (Switzerland) · CHYokohama City University Hospital · JP

Funding

Japan Society for the Promotion of Science 19K09873Japan Society for the Promotion of Science 19K09895Japan Society for the Promotion of Science 21K09612Japan Society for the Promotion of Science 21K09636Ministry of Education, Culture, Sports, Science and Technology 11800122Yokohama City University 2019-112
6 · The paper itself

Abstract

purposeDepending on its histological subtype, salivary gland carcinoma (SGC) may have a poor prognosis. Due to the scarcity of preclinical experimental models, its molecular biology has so far remained largely unknown, hampering the development of new treatment modalities for patients with these malignancies. The aim of this study was to generate experimental human SGC models of multiple histological subtypes using patient-derived xenograft (PDX) and organoid culture techniques.

methodsTumor specimens from surgically resected SGCs were processed for the preparation of PDXs and patient-derived organoids (PDOs). Specimens from SGC PDXs were also processed for PDX-derived organoid (PDXO) generation. In vivo tumorigenicity was assessed using orthotopic transplantation of SGC organoids. The pathological characteristics of each model were compared to those of the original tumors using immunohistochemistry. RNA-seq was used to analyze the genetic traits of our models.

resultsThree series of PDOs, PDXs and PDXOs of salivary duct carcinomas, one series of PDOs, PDXs and PDXOs of mucoepidermoid carcinomas and PDXs of myoepithelial carcinomas were successfully generated. We found that PDXs and orthotopic transplants from PDOs/PDXOs showed similar histological features as the original tumors. Our models also retained their genetic traits, i.e., transcription profiles, genomic variants and fusion genes of the corresponding histological subtypes.

conclusionWe report the generation of SGC PDOs, PDXs and PDXOs of multiple histological subtypes, recapitulating the histological and genetical characteristics of the original tumors. These experimental SGC models may serve as a useful resource for the development of novel therapeutic strategies and for investigating the molecular mechanisms underlying the development of these malignancies.

Indexed as

Salivary Gland NeoplasmsAnimalsDisease Models, AnimalHumansOrganoidsPhenotypeTransplantation, HeterologousXenograft Model Antitumor AssaysOrganoid culturePatient-derived organoid (PDO)Patient derived xenograft (PDX)PDX-derived organoid (PDXO)Salivary gland cancer

Identifiers

PMID36538240
PMCPMC10060313
OpenAlexW4312019279

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.